Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00253630
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
- Conditions
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00251589
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00243100
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 103
- Registration Number
- NCT00238303
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT00227513
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3)Childhood Atypical Teratoid/Rhabdoid TumorChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaJuvenile Myelomonocytic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Grade III Lymphomatoid Granulomatosis
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00217412
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00138177
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00138203
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Gundersen Lutheran, La Crosse, Wisconsin, United States
🇺🇸Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00134043
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT00132002
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.